Haiyan Jiang Email & Phone Number

San Diego, Ca, Us

• Led new R&D direction focused on immuno-oncology• Built internal oncology research capability• Made significant advancement in 3 novel therapeutic programs in NK, CAR NK and immunemodulatory bispecific antibody• Built external KOL networks and managed academic and industry collaborations• Provided scientific and technical guidance in due diligence for business development

Shanghai, Cn

• Established internal R&D capability and initiated 4 pipeline programs• Responsible for R&D collaboration strategy in discussion with potential partners, and providedscientific and technical guidance to BD in evaluating potential in-license opportunities

Cambridge, Ma, Us

• Recruited key leadership talents including the Head of Clinical Development and Head of Technology• Developed R&D strategy of AAV-mediated gene therapy for genetic diseases and ex vivo cell therapyfor cancers• Interacted with investors to support series A fund raising

Cambridge, Massachusetts, Us

• Built translational capabilities, including pharmacology specialized in in vivo ophthalmology and ex vivo cell therapy, histology, safety immunology and bioanalytical to support preclinical and clinical development.• Led the preclinical development strategy for EDIT-101, a subretinally delivered AAV-CRISPR/Cas9 for treatment of Leber Congenital Amaurosis type 10. Oversaw and managed pharmacology and safety studies in-house and at CROs. Led successful nonclinical interactions with FDA during pre-pre-IND and pre-IND.• Provided high level scientific guidance and development strategy on hematopoietic stem cell - based genome editing therapy for sickle cell disease. Advocated and supported a new Lenti-CRISPR screen of a 340 kb genomic region centered around the beta-globin locus that led to identification of novel therapeutic targets. • Developed active scientific dialog and collaboration with scientists at OTAT/CBER/FDA on evaluation of Cas9 immunogenicity.

Cambridge, Ma, Us

• Responsible for hematology cell & gene therapy research programs, including:[1] in vivo delivery of liver-targeted lentiviral FIX/FVIII vector for hemophilia, in collaboration with Luigi Naldini group at TIGET/San Raffaele Hospital[2] ZFN-driven BCL11A genome editing in autologous hematopoietic stem and progenitor cells for sickle cell disease and β-thalassemia, in alliance with Sangamo BioScience• Worked with Business Development and Corporate Strategy on developing and implementing strategies for benign hematology and gene therapy. Evaluated broadly in-licensing opportunities for rare diseases and gene therapy platform technology• Established specialized coagulation assays and quantitative bleeding models in hemophiliac mice to determine the correlation in PK/PD and efficacy. Candidate validation in animal models from mice to monkeys, MoA and immunogenicity research, IND-enabling pharmacology and safety studies• Contributed to the clinical protocol development for the pivotal trials for rFIXFc (Alprolix) and rFVIIIFc (Eloctate), clinical PK data analysis, population PK modeling and simulations, preclinical and clinical pharmacology in Biologics License Applications and related regulatory interactions• Identified XTEN technology and initiated collaboration with Amunix for pipeline research on next generation longer-acting coagulation factors

Leverkusen, North Rhine-Westphalia, De

• Research and preclinical pharmacology in support of IND and IMPD of site-specifically PEGylated FVIII (Bay 94-9027)• Cross-functional MoA study to support Kogenate-PEG-Liposome (Bay 79-4980) phase 2 clinical trial • Pharmacology due diligence and tech transfer of FVIIa program acquired from Maxygen, and subsequent preclinical evaluation of Bay7 (Bay 86-6150)• Early stage research on next generation pro-coagulant therapeutics• Evaluation of various in-licensing opportunities and due diligence• Managed academic collaborations and contract studies at CROs

Us

• Non-clinical research on clinical trial subjects and healthy volunteers to support the phase 1 clinical trials on muscle- or liver-targeted, adeno-associated viral (AAV) vector mediated gene therapy for the treatment of severe Hemophilia B• Research and preclinical studies of AAV-FVIII gene therapy for Hemophilia A in diseased animal models (mice and dogs)

San Francisco, California, Us

Ph.D, Oncology

Bs, Biochemistry